Clinical Trial Highlights

• Single-Pill Combination Therapy for the Treatment of Severe Hypertension
• Aliskiren-Based Therapy Controls Blood Pressure Regardless of Plasma Renin Activity
• A Different Analytic Approach to Assess J-Curve Findings from the FEVER Trial
• An Innovative Approach to Cardiovascular Risk Reduction: Results from the C-CHAP Study
• All Patients with Uncontrolled Blood Pressure on Valsartan Monotherapy Benefit from Switch to Combination Therapy
• Olmesartan Reduces Microalbuminuria in Patients with Type 2 Diabetes
• Self-Management Better than Usual Care in Reducing Blood Pressure Levels in Patients with Uncontrolled Hypertension
• The Potential Blood Pressure Lowering Benefit of Azilsartan Medoxomil
• Candesartan and Amlodipine: Effect on the Incidence of Cardiovascular Events and New-Onset Diabetes
• First-Line Treatment with Combination Aliskiren/Amlodipine Improves Blood Pressure Control over Amlodipine Alone in Moderate and Severe Hypertension
• Olmesartan Medoxomil versus Ramipril for the Treatment of Hypertension in the Elderly
• Results from the ACCORD BP Trial